The Cancer Letter

Inside information on cancer research and drug development

In Brief

Laura Brod named CEO of GeneSegues Therapeutics

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

LAURA BROD was named CEO of GeneSegues Therapeutics. Brod is an at-large member of the University of Minnesota Board of Regents and is chair of the university’s Audit Committee. She was a member of the Minnesota House of Representatives from 2002 to 2010, during which time she served as assistant majority leader.

GeneSegues is based in Minneapolis and develops DNA and RNAi cancer therapeutics using sub-50 nanometer nanocapsule technology, including GS-10, for the treatment of a range of solid tumor cancers including head and neck, prostate and breast, as well as their related metastases.

Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Rathmell: My mentor recognized a cliff I was going to fall off before I did.
“He was there to stand with me while I fell, and then made me look up and see that I needed to lean into the experience.”

I was really excited to get to talk about the role that mentorship plays in women’s leadership development. It’s a topic that I’ve thought a lot about, and also that I’ve benefitted from, and that I think is not always applied with enough intention. There is an art to mentorship, and I want to share some of how that has helped me navigate career transitions and pivot to leadership roles.
By W. Kimryn Rathmell
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account